TABLE 2.

Azole use in the hospital setting (DDD/1,000 discharges) and in the primary health care sector (DDD/1,000 inhabitants) served by the six centers^a

Parameter	County of Copenhagen	County of Funen	County of Aarhus	County of North Jutland	Rigshospitalet	Hvidovre, Copenhagen City hospitals
No. of fungal BSI with reduced susceptibility to azoles	5 (14%)	10 (21%)	18 (32%)	22 (38%)	17b (26%b)	17b (38%b)
Hospital setting (DDD/1,000 discharges)
Fluconazole
2002	87.06	167.82	111.87	66.85	598.91	139.64
2003	86.38	143.84	107.91	80.99	802.56	121.00
Itraconazole
2002	6.43	77.55	15.51	8.80	121.82	18.38
2003	1.62	83.83	19.37	3.53	83.94	20.72
Primary health care setting (DDD/1,000 inhabitants)
Fluconazole
2002	43.67	38.1	37.08	29.7	48.85c
2003	48.19	42.11	40.74	36.33	53.15c
Itraconazole
2002	62.31	67.53	68.56	49.66	77.78c
2003	67.05	67.2	63.31	58.31	79.49c

^aCenters were ranked according to the proportion of C. albicans isolates, and the total number of fungal BSI with reduced azole susceptibility is indicated.

^bNot all isolates from Rigshospitalet and Hvidovre were susceptibility tested, making the number and percentage minimum figures.

^cData of azole usage for the population in the Copenhagen area were available only for the joined regions served by Rigshospitalet and Hvidovre.